Desmopressin Acetate (Desmopressin Acetate) Patent Expiration, LOE Window & CMS Spending

Desmopressin Acetate (Desmopressin Acetate) by Ferring: Off-Patent Genericized (AB Competition), 5 AB generics, $30.5M 2024 CMS Part D & Medicaid spend, and $395 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFerring
FDA Application & PathwayN021795 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$30.5M
2024 Medicare Part D Spend$15.4M
2024 Medicaid Spend$15.1M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($395 intro WAC)